GlassScriptPhysician profile
Michael A Kia
NPI 1477590842
$2,001.74
in general payments reported to CMS, 2019-2025
20 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $181 · 2021: $574 · 2022: $331 · 2023: $298 · 2024: $193 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $707.16 | 2021-2025 | Signia, Progrip, Surgineedle |
| Ethicon US, LLC | $389.00 | 2019-2025 | Echelon Endopath, Vistaseal, Harmonic |
| Intuitive Surgical, INC. | $160.38 | 2023-2024 | |
| Baxter Healthcare | $154.87 | 2020-2023 | Peri-Strips Dry |
| Merck Sharp & Dohme LLC | $97.08 | 2019-2024 | Bridion |
| Eisai INC. | $60.47 | 2021 | |
| Allergan, INC. | $46.53 | 2021-2022 | |
| Covidien LP | $44.33 | 2019 | |
| Aroa Biosurgery Incorporated | $42.86 | 2019-2023 | |
| Tela Bio, INC. | $38.30 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Shire North American Group INC | $33.70 | 2019 | |
| Smith+Nephew, INC. | $33.38 | 2023-2024 | Stravix |
| Takeda Pharmaceuticals U.S.A., INC. | $32.65 | 2020-2021 | |
| Davol INC. | $32.32 | 2025 | Phasix Mesh |
| Abbvie INC. | $27.35 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $26.38 | 2025 | Fibryga |
| Heron Therapeutics, INC. | $21.68 | 2022 | |
| Innocoll Pharmaceuticals Limited | $20.76 | 2021 | |
| Myriad Genetic Laboratories, INC. | $16.57 | 2024 | Myrisk |
| Acacia Pharma INC | $15.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.